Trial Profile
Phase II Clinical Study of Lapatinib (GW572016) in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 24 Mar 2010 Actual patient number (62) added as reported by ClinicalTrials.gov.
- 28 Jul 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 28 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.